A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Non-small Cell Lung Carcinoma (NSCLC) Clinical Trial

Official title:

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, Non Small-Cell Lung Cancer That Has Metastasized to the Brain

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04460729
• Other study ID #: CINC280A2203
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 11, 2020
• Est. completion date: November 17, 2023

Study information

• Verified date: November 2020
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to establish the intracranial efficacy of single agent capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of systemic therapies for advanced stage Non Small-Cell Lung Cancer (NSCLC) with MET exon 14 mutation that has metastasized to the brain. Cohort 1 (asymptomatic brain metastases (BM) without prior brain therapy) has been selected to identify patients who are most likely to benefit from capmatinib therapy in this setting and to establish a clinically relevant response outcome. Cohort 2 is a heterogeneous group of patients (symptomatic with and without prior brain therapy, asymptomatic with prior brain therapy, or with leptomeningeal disease.), and the outcomes will be descriptive only

Description:

This is a prospectively designed, multicenter, open-label, two-cohort, phase II study to evaluate the intracranial efficacy of single agent capmatinib in participants with MET exon 14 mutated NSCLC and BM. Participants can be treatment naïve or pretreated with one or two prior lines of systemic therapies for advanced stage (stage IIIb - IV) NSCLC. Approximately 60 participants will be enrolled globally and allocated to one of two cohorts: Cohort 1 will enroll approximately 40 participants who are asymptomatic and without prior brain therapy. Cohort 2 will enroll approximately 20 participants who are symptomatic with or without prior brain therapy or asymptomatic with prior brain therapy or with leptomeningeal disease. All participants will be pre-screened for MET mutation and presence of BM will be documented at baseline by a radiologist/neuroradiologist. Intracranial disease will be assessed and response to treatment will be evaluated using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria every 8 weeks. Extracranial and whole body disease will be assessed and response to treatment will be evaluated using RECIST 1.1 every 8 weeks. Participants will receive capmatinib 400 mg b.i.d. until they experience any of the following: documented disease progression by RANO-BM criteria and/or RECIST 1.1 (as assessed by the investigator and confirmed by BIRC), withdrawal of consent, pregnancy, lost to follow-up, or death. For all participants, treatment with capmatinib may be continued beyond initial progression disease (PD) as per RANO-BM criteria and/or RECIST 1.1 (as assessed by the investigator and confirmed by BIRC) if, in the judgment of the investigator, there is evidence of clinical benefit, and the participant wishes to continue on the study treatment. After treatment discontinuation, all participants will be followed for safety evaluations during the safety follow-up period, and the participant's status will be collected every 12 weeks as part of the survival follow-up.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 17, 2023
• Est. primary completion date: November 17, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed stage IV (according to Version 8 of the American Joint Committee on Cancer (AJCC)) NSCLC that is EGFR wt, ALK rearrangement negative as assessed by a validated test as part of the participant's standard of care and has MET?ex14 mutation per Novartis-designated central laboratory or (US only) locally with FoundationOne Companion Diagnostic (F1CDx) .
• Treatment naïve or up to two prior lines of systemic therapy for stage IIIb-IV NSCLC
• Measurable intracranial lesions:

1. Cohort 1 and Cohort 2 (without leptomeningeal carcinoma): At least 1 measurable intracranial lesion per RANO-BM criteria, documented by a radiologist/neuroradiologist (treated or untreated).

2. Cohort 2 (with leptomeningeal carcinoma): participants with leptomeningeal carcinoma may not have measurable lesions. In this circumstance, the participant's disease will be considered to have non-target lesions only at baseline and their response based on descriptive clinical criteria by physician assessment.

• Capable of undergoing magnetic resonance imaging (MRI)
• ECOG performance status of 0 or 1

Exclusion Criteria:

• Only for Cohort 1: any neurological symptoms related to brain metastases
• For participants in Cohort 2 with prior brain therapy: Treatment with stereotactic radiosurgery within 14 days prior to the start of study treatment or treatment with WBRT within 14 days prior to the start of study treatment
• Prior treatment with any MET targeting therapy or HGF inhibitor
• Participants with other known druggable molecular alterations (such as ROS1 translocation or BRAF mutation) who might be candidates to alternative targeted therapies as applicable per local regulations and treatment guidelines
• Presence or history of ILD or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention)
• Clinically significant, uncontrolled heart diseases including History of familial long QT syndrome, sudden death or congenital long QT syndrome Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Carcinoma (NSCLC)

Intervention

Drug:
• Capmatinib
400 mg administered orally twice daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Intracranial Response Rate (OIRR) in Cohort 1 by Blinded Independent Review Committee (BIRC) review	Overall Intracranial Response Rate (OIRR) in Cohort 1, defined as the proportion of participants with a confirmed best intracranial overall response of Complete Response (CR) or Partial Response (PR) per RANO-BM criteria as assessed by BIRC review	Up to 36 months
Secondary	Overall Intracranial Response Rate (OIRR) in Cohort 1 by investigator review	Overall Intracranial Response Rate (OIRR) in Cohort 1, defined as the proportion of participants with a confirmed best intracranial overall response of Complete Response (CR) or Partial Response (PR) per RANO-BM criteria as assessed by investigator review	Up to 36 months
Secondary	Intracranial Disease Control Rate (IDCR) by investigator and BIRC review	Intracranial Disease Control Rate (IDCR) per RANO-BM criteria as assessed by investigator review and by BIRC review	Up to 36 months
Secondary	Time to intracranial tumor Response (TTIR) by investigator and BIRC review	Time to intracranial tumor Response (TTIR) per RANO-BM criteria as assessed by investigator review and by BIRC review	Up to 36 months
Secondary	Duration of Intracranial Response (DOIR) by investigator and BIRC review	Duration of Intracranial Response (DOIR) per RANO-BM as assessed by investigator review and by BIRC review	Up to 36 months
Secondary	Overall Intracranial Response Rate (OIRR) in Cohort 2 by investigator and BIRC review	Overall Intracranial Response Rate (OIRR) per RANO-BM criteria in Cohort 2 by investigator review and by BIRC review	Up to 36 months
Secondary	Overall Extracranial Response Rate (OERR) by investigator and BIRC review	Overall Extracranial Response Rate (OERR) per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Extracranial Disease Control Rate (EDCR) by investigator and BIRC review	Extracranial Disease Control Rate (EDCR) per RECIST 1.1 by investigator and BIRC review	Up to 36 months
Secondary	Time to Extracranial Response (TTER) by investigator and BIRC review	Time to Extracranial Response (TTER) per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Duration of Extracranial Response (DOER) by investigator and BIRC review	Duration of Extracranial Response (DOER) per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Overall Response Rate (ORR) per RECIST 1.1 by investigator and BIRC review	Overall Response Rate (ORR) in the whole body per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Time to response (TTR) by investigator and BIRC review	Time to response (TTR) in the whole body per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Duration of response (DOR) by investigator and BIRC review	Duration of response (DOR) in the whole body per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Progression free survival (PFS) by investigator and BIRC review	Progression free survival (PFS) in the whole body per RECIST 1.1 by investigator review and by BIRC review	Up to 36 months
Secondary	Overall survival (OS)	Overall survival (OS) is defined as the time from the date of start of treatment to the date of death due to any cause.	Up to 36 months
Secondary	Percentage of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)	Safety profile of capmatinib. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) including any clinically significant lab, vital signs, ECG abnormalities that are captured as an AE	Up to 36 months
Secondary	Number of participants with dose interruptions	Tolerability measured by the number of subjects who have interruptions of study treatment	Up to 29 months
Secondary	Number of participants with dose reductions	Tolerability measured by the number of subjects who have reductions of study treatment	Up to 29 months
Secondary	Dose intensity	Tolerability measured by the dose intensity of study drug computed as the ratio of actual cumulative dose received and actual duration of exposure	Up to 29 months
Secondary	Time to deterioration in Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) scores in Cohort 1	Time to deterioration in symptoms of brain metastases in Cohort 1 with the Functional Assessment of Cancer Therapy (FACT)-Brain Symptom Index (FBrSI) (a standardized questionnaire developed to assess the quality of life of cancer patients)	Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
Secondary	Change from baseline in score as per FACT-Brain Symptom Index (FBrSI) in Cohort 2	Change from baseline in symptoms of brain metastases in Cohort 2 with the FACT-Brain Symptom Index (FBrSI) (a standardized questionnaire developed to assess the quality of life of cancer patients)	Day 1 and 15 of Cycle 1, Day 1 of cycles 2 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
Secondary	Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30	Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the EORTC QLQ-C30 (a 30-item questionnaire developed to assess the quality of life of cancer patients)	Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
Secondary	Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13)	Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the QLQ-LC13 (a 13-item questionnaire developed to assess the quality of life of cancer patients)	Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days
Secondary	Change from baseline in score as per European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire	Change from baseline in lung cancer related symptoms, functioning and other domains of HRQoL in both cohorts with the EQ-5D-5L (a standardized questionnaire developed to assess the quality of life of cancer patients)	Day 1 of cycle 1 to 11 and then every other cycle until end of treatment (up to 29 months). Cycle=28 days